Shanghai Pharmaceuticals Holding Co Ltd
SWB:S1R
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Shanghai Pharmaceuticals Holding Co Ltd
SWB:S1R
|
CN |
|
Slater & Gordon Ltd
ASX:SGH
|
AU |
|
G
|
General Mills Inc
XETRA:GRM
|
US |
|
S
|
State Bank of India
BSE:500112
|
IN |
|
EssilorLuxottica SA
XETRA:ESL
|
FR |
|
A
|
Axcelis Technologies Inc
F:XXA1
|
US |
|
V
|
Volvo AB
DUS:VOL1
|
SE |
|
G
|
Grindrod Ltd
JSE:GND
|
ZA |
|
Okinawa Cellular Telephone Co
TSE:9436
|
JP |
|
Hengli Petrochemical Co Ltd
SSE:600346
|
CN |
Wall St Price Targets
S1R Price Targets Summary
Shanghai Pharmaceuticals Holding Co Ltd
According to Wall Street analysts, the average 1-year price target for S1R is 1.51 EUR with a low forecast of 0.92 EUR and a high forecast of 1.87 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is S1R's stock price target?
Price Target
1.51
EUR
According to Wall Street analysts, the average 1-year price target for S1R is 1.51 EUR with a low forecast of 0.92 EUR and a high forecast of 1.87 EUR.
What is the Revenue forecast for Shanghai Pharmaceuticals Holding Co Ltd?
Projected CAGR
7%
Over the last 14 years, the compound annual growth rate for Revenue has been 12%. The projected CAGR for the next 3 years is 7%.
What is the Operating Income forecast for Shanghai Pharmaceuticals Holding Co Ltd?
Projected CAGR
8%
Over the last 14 years, the compound annual growth rate for Operating Income has been 10%. The projected CAGR for the next 3 years is 8%.
What is the Net Income forecast for Shanghai Pharmaceuticals Holding Co Ltd?
Projected CAGR
5%
Over the last 14 years, the compound annual growth rate for Net Income has been 8%. The projected CAGR for the next 3 years is 5%.
